Vaxcyte Inc (PCVX)

R&D Expense Growth

-14.36%

Quarterly · Period ending:

PCVX logo

PCVX R&D Expense Growth

Latest reported-14.36%
PCVX Quarterly R&D Growth (QoQ) (0.00% → -14.36%)
High-resolution chart · PNG

PCVX r&d expense growth history

Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.

Vaxcyte Inc R&D Expense Growth — Quarterly
Period endingR&D Expense Growth
-14.3638%
29.2155%
15.3035%
8.1131%
31.0833%
10.8671%
14.2625%
-11.08%
39.0328%
-9.1819%
6.9071%
34.0207%
25.1567%
12.5015%
8.2783%
23.9414%
21.4376%
37.2887%
12.9528%
15.7328%
2.2772%
17.7137%
-10.6581%
-9.726%
-25.2396%
81.6993%
38.9616%
-3.3909%
-21.0643%
0%
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.